Intellia Therapeutics (NTLA) Covered By Yet Another Research Firm

Why Has Leerink Partners Given Intellia Therapeutics (NTLA) a $23.0000 Price Target

Leerink Partners analyst began coverage on Intellia Therapeutics (NTLA) with a $23.0000 TP and Buy rating. The TP gives a potential upside of 28.42 % from company’s close price.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Ratings Coverage

Among 3 analysts covering Intellia Therapeutics (NTLA), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Intellia Therapeutics has $23 highest and $20 lowest target. $21.50’s average target is 20.04% above currents $17.91 stock price. Intellia Therapeutics had 3 analyst reports since September 21, 2018 according to SRatingsIntel. The stock of Intellia Therapeutics, Inc. (NASDAQ:NTLA) has “Neutral” rating given on Friday, November 2 by Wedbush.

The stock increased 2.28% or $0.4 during the last trading session, reaching $17.91. About 274,838 shares traded. Intellia Therapeutics, Inc. (NTLA) has risen 42.05% since December 2, 2017 and is uptrending. It has outperformed by 26.43% the S&P500.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $777.64 million. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

More notable recent Intellia Therapeutics, Inc. (NASDAQ:NTLA) news were published by: which released: “CRISPR advances as second gene-altered pregnancy revealed – Seeking Alpha” on November 28, 2018, also with their article: “Intellia Therapeutics: Left Behind The Cas9 Excitement – Seeking Alpha” published on July 22, 2018, published: “JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action – Seeking Alpha” on November 02, 2018. More interesting news about Intellia Therapeutics, Inc. (NASDAQ:NTLA) were released by: and their article: “Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy – GlobeNewswire” published on October 18, 2018 as well as‘s news article titled: “Here’s Why CRISPR Stocks Rose as Much as 18.7% in August – Motley Fool” with publication date: September 04, 2018.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.